Zoetis (ZTS) Cash from Financing Activities (2012 - 2026)
Zoetis' (ZTS) quarterly Cash from Financing Activities came in at -$840.0 million in Q1 2026, down 24.08% year-on-year from -$1.1 billion in Q1 2025, and down 69.7% on a QoQ basis from -$495.0 million in Q4 2025.
Zoetis (ZTS) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Cash from Financing Activities data on file, last reported at -$840.0 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 24.08% year-over-year to -$840.0 million in Q1 2026; TTM through Mar 2026 was -$2.0 billion, a 27.73% increase from a year earlier, with the FY2025 full-year figure at -$1.9 billion, up 29.7% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$840.0 million, down from -$495.0 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for ZTS reached as high as $780.0 million in Q4 2022 and fell as low as -$1.8 billion in Q1 2023.
- Historically, Cash from Financing Activities has averaged -$551.9 million across 5 years, with a median of -$545.0 million in 2022.
- Across the five-year window, Cash from Financing Activities soared 348.41% in 2022 and tumbled 230.64% in 2023, its largest moves.
- Year by year, Cash from Financing Activities stood at $780.0 million in 2022, then sank by 150.9% to -$397.0 million in 2023, then slumped by 87.66% to -$745.0 million in 2024, then surged by 33.56% to -$495.0 million in 2025, then tumbled by 69.7% to -$840.0 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$840.0 million in Q1 2026, -$495.0 million in Q4 2025, and -$134.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -840.00 Mn |
| Mar 31, 2026 | -840.00 Mn |
| Dec 31, 2025 | -495.00 Mn |
| Dec 31, 2025 | -495.00 Mn |
| Sep 30, 2025 | -134.00 Mn |
| Sep 30, 2025 | -134.00 Mn |
| Jun 30, 2025 | -564.00 Mn |
| Jun 30, 2025 | -564.00 Mn |
| Mar 31, 2025 | -677.00 Mn |
| Mar 31, 2025 | -677.00 Mn |
| Dec 31, 2024 | -745.00 Mn |
| Dec 31, 2024 | -745.00 Mn |
| Sep 30, 2024 | -628.00 Mn |
| Sep 30, 2024 | -628.00 Mn |
| Jun 30, 2024 | -763.00 Mn |
| Jun 30, 2024 | -763.00 Mn |
| Mar 31, 2024 | -524.00 Mn |
| Mar 31, 2024 | -524.00 Mn |
| Dec 31, 2023 | -397.00 Mn |
| Dec 31, 2023 | -397.00 Mn |